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a b s t r a c t
The complement cascade is a highly sophisticated network of proteins that are well regulated and
directed in response to invading pathogens or tissue injury. Complement C3a and C5a are key mediators
produced by this cascade, and their dysregulation has been linked to a plethora of inﬂammatory and
autoimmune diseases. Consequently, this has stimulated interest in the development of ligands for the
receptors for these complement peptides, C3a receptor, and C5a1 (C5aR/CD88). In this study we used
computational methods to design novel C5a1 receptor ligands. However, functional screening in human
monocyte-derived macrophages using the xCELLigence label-free platform demonstrated altered
speciﬁcity of our ligands. No agonist/antagonist activity was observed at C5a1, but we instead saw that
the ligands were able to partially agonize the closely related complement receptor C3a receptor. This was
veriﬁed in the presence of C3a receptor antagonist SB 290157 and in a stable cell line expressing either
C5a1 or C3a receptor alone. C3a agonism has been suggested to be a potential treatment of acute
neutrophil-driven traumatic pathologies, and may have great potential as a therapeutic avenue in
this arena.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Complement activation proceeds through cascades of enzy-
matic reactions leading to inﬂammation, phagocytosis, lysis, and
augmentation of antibody production (Markiewski and Lambris,
2007). Two major products of complement activation are the
protein fragments C3a and C5a, beneﬁcial in infections but also
mediating inﬂammatory diseases (Peng et al., 2009).
C5a exerts a number of effects through its classical receptor,
C5a1 (C5aR/CD88) (Klos et al., 2013), such as recruiting neutrophils
and macrophages to sites of injury, releasing granule-associated
enzymes and vasoactive mediators, increasing vascular perme-
ability and adhesion, inducing smooth muscle contractions and
stimulating the release of proinﬂammatory cytokines. C5a also
interacts with a second receptor, C5a2, although the functions of
this receptor are not fully determined (Croker et al., 2013; Li et al.,
2013). Increased amounts of C5a are associated with a number of
pathological conditions, including lupus, ischemia/reperfusion
injury, Crohn's disease, cystic ﬁbrosis, gingivitis, atherosclerosis,
myocardial infarction, ﬁbrosis, allergy, diabetes type I, and dis-
orders of the central nervous system (Manthey et al., 2009).
Inhibition of C3a and C5a interactions with their respective
receptors, C3a receptor and C5a1, has been targeted for drug design
(Bellows-Peterson et al., 2012; Monk et al., 2007). However, a recent
study has suggested that C3a and C5a1 have opposing roles in
neutrophil-mediated pathology (Wu et al., 2013). In a model of
intestinal injury, the authors of this study showed that C3a receptor
is not chemotactic for neutrophils, but rather, constrains neutrophil
mobilization. Therefore C3a receptor agonism and C5a1 antagonism
may have similar therapeutic effects in acute neutrophil-driven
pathologies (Schoﬁeld et al., 2013).
C3a and C5a are 77- and 74-residue proteins, with 32% sequence
identity and similar three-dimensional structures (Klos et al., 2013).
A common mechanism of function utilizes the C-terminal cationic
domainwhich inserts into the activation site of respective receptors.
Removal of the conserved C-terminal arginine has complex effects
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on functionality (Croker et al., 2013; Reis et al., 2012). Past drug
design efforts have focused on designing peptides and peptidomi-
metics by modifying the C-terminal regions (Klos et al., 2013).
Additional recent efforts have focused on using both sequence and
structural templates with innovative computational methods to
design C3a receptor agonist and antagonist peptides (Bellows-
Peterson et al., 2012), including the current study.
A two-stage de novo protein design framework previously
described (Bellows-Peterson et al., 2012; Bellows et al., 2010a,
2010b; Fung et al., 2008, 2005, 2007; Klepeis et al., 2003, 2004)
was applied to the design of C5a-derived peptides. The peptides
were functionally screened on the reporter cell line, RBL-2H3
transfected with human C3a receptor or C5a1 or on human
monocyte-derived macrophages (HMDM) using label-free meth-
ods that provided cell activation read-outs. Several hits were
identiﬁed and, based on the activation proﬁles, these hits appeared
to be C3a agonists. Screening of the peptides in the presence of
C3a receptor and C5a1 antagonists conﬁrmed C3a receptor as the
target. Thus modiﬁcation to the C-terminal sequence conferred
C3a agonist activity on C5a peptides.
2. Materials and methods
2.1. Computational design of peptides
The computational design framework (described in detail in
Supplementary material) was broadly as described previously
(Bellows-Peterson et al., 2012).
2.2. Peptide synthesis
All octa-, hepta-, and hexapeptides tested were synthesized by
GenScript (Piscataway, NJ) with acetylated N-termini at 495%
purity. Purity was conﬁrmed with HPLC. The C-terminus was
unblocked in all peptides.
2.3. Cell culture
Human monocytes were isolated from blood donations to the
Australian Red Cross Blood Service (Kelvin Grove, Queensland).
The isolation of mononuclear cells was as described previously by
Halai and Cooper (2012). Brieﬂy, the mononuclear cell layer was
separated using density gradient centrifugation with Ficoll-Paque
Plus (GE Healthcare). MACS magnetic beads (Miltenyi Biotec) were
incubated with the cells for 15 min at 4 1C before passing through
an LS column (Miltenyi Biotec) to select for the CD14þ cells.
Selected monocytes were plated at a density of 1.5107 in Iscove's
Modiﬁed Dulbecco's Medium (IMDM) (Invitrogen Life Technolo-
gies) containing L-glutamine supplemented with 10% Fetal Bovine
Serum (FBS), 50 IU/ml penicillin and 50 μg/ml streptomycin.
Human macrophage colony-stimulating factor (M-CSF) (Pepro-
tech) was added to media to allow cells to differentiate into
human monocyte-derived macrophages (HMDM). Over the 7 day
differentiation process, cells were incubated at 37 1C and 5% CO2.
2.4. Cell impedance assay (xCELLigence RTCA)
HMDM were seeded overnight at 30,000 cells/well in 384-well
E-Plates (Roche). Approximately 24 h later, HMDM media were
exchanged for serum-free IMDM and equilibrated at 37 1C and 5%
CO2 for 2 h prior to ligand addition. Ligands were prepared at a ﬁnal
DMSO concentration of 0.5% (or less) in serum-free IMDM. Antago-
nists PMX53 and SB 290157 were incubated for 1 h prior to agonist
addition, at concentration ranges known to cause substantial inhibi-
tion of receptor activation in these cells. After agonist addition,
measurements were taken continuously for 1.5 h at 37 1C. The
RTCA software was used for data analysis, with statistical analysis
using GraphPad Prism 5.0c (GraphPAD Software Inc., San Diego, CA).
2.5. Rat basophilic leukemia cell degranulation assay
RBL-2H3 cells transfected with either human C5a1 or human C3a
receptor (Cain and Monk, 2002) were routinely cultured in Dulbecco's
Modiﬁed Eagle's Medium, 10% (v/v) fetal calf serum, and 400 mg/l
G-418 at 37 1C in 5% CO2. Degranulationwas measured by assaying for
β-hexosaminidase activity in the cell supernatant, as described
previously (Monk et al., 1994). In agonist assays, degranulation was
calculated as a percentage of maximal activity in response to 200 nM
recombinant human C3a, human C5a (Cain and Monk, 2002), or
10 nM agonist hexapeptide, FLPLAR (Scully et al., 2010). For antagonist
assays, cells were pretreated with peptides for 10 min prior to the
addition of C3a, C5a, or FLPLAR. EC50, IC50, and standard error values
were obtained by iterative curve ﬁtting in GraphPad Prism v5.0.
3. Results
3.1. Computational results
For each run (Supplementary Table 1), 200 peptide sequences
were generated using the Distance Bin Model (Fung et al., 2008;
Rajgaria et al., 2008). This produced 6400 total sequences. Each
sequence was subjected to fold speciﬁcity calculations using both
AMBER and FAMBE-pH and ranked accordingly. Top sequences
from each run are combined in Supplementary Table 2. The
sequences shown were either the top few sequences in the run,
or sequences that showed promising features such as a charged
residue in positions 67 or 68 or a hydrophobic residue in position
70 or 72 (as in the native sequence).
The designed peptide sequences displayed a number of patterns,
including the mutation to Trp in position 73 (also seen in the most
potent antagonists thus far (Finch et al., 1999)) and the preference
for a charged residue in position 68. Position 68 showed a
preference for a charge residue, either positive or negative. When
positively charged, the amino acid of choice was Arg, as opposed to
the native Lys. Nearly all the runs tended to rank a hydrophobic
residue in position 70 highly, despite the fact that all the templates
also allowed hydrophilic residues in that position.
3.2. Screening peptides on HMDM using the xCELLigence
The 61 peptides, initially dissolved in dimethyl sulfoxide
(DMSO) at 10 mM, were screened at a single dose of 8 μM on
HMDM using an impedance based label-free system, the xCELLi-
gence; DMSO at o0.5% was found to have no effects in this assay.
Fig. 1A shows the identiﬁcation of 5 signiﬁcant hits (Po0.001),
peptides 20, 31, 47, 48 and 54. Peptide 49 was identiﬁed as a
potential hit from independent data (data not shown) despite not
evoking a response in the initial screen and so was retested at the
full dose range along with the ﬁve identiﬁed hits (see Fig. 1B).
Interestingly, a full dose response could not be obtained for
peptide 48 (data not shown). However, peptide 49 showed weak
activity, despite failing in the initial single dose screen. The EC50 of
the hits has been summarized in Table 1.
3.3. Identifying the target receptor for the hits
Using the xCELLigence, the hits were tested in the presence of both
the C3a receptor and C5a1 antagonists, SB 290157 and PMX53,
respectively (see Fig. 1C and D). A dose dependent inhibition of the
cell index was observed for peptides 20, 31, 47, 49 and 54 in the
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presence of the competitive antagonist SB 290157 when activated
with a concentration of peptide approximating to the EC50. The IC50 of
SB 290157 in the presence of peptides 20, 31, 47, 49 and 54 is
highlighted in Table 1. No change was observed in the peptide-evoked
cell index in the presence of PMX53 (see Fig. 1D). The xCELLigence
activation proﬁles are depicted in Fig. 2, where all the peptides even at
a very high dose (100 mM) have a monophasic proﬁle more similar to
that of C3a than of C5a. Despite some being partial agonists at the C3a
receptor, none of the peptides were able to antagonize C3a activation
of HMDM when tested at 10 mM (data not shown).
3.4. Rat basophilic leukemia cell degranulation assay
RBL-2H3 cells transfected with either human C5a1 or human C3a
receptor (Cain and Monk, 2002) were used to conﬁrm hits detected
in HMDM, using degranulation as a read-out (Monk et al., 1994). In
cells transfected with C5a1, very weak agonist activity was detected
in two groups of peptides, although even at 100 mM (the maximal
dose achievable in the presence of the DMSO, which has adverse
effects 41%), the activation obtained was 5–10% of the maximum
activation achieved by a high dose of C5a (Fig. 3, top panel). In
contrast, two peptides (31 and 54) produced very strong activation
of C3a receptor (Fig. 3, lower panel) at 100 mM. In antagonist assays
using two different doses of C5a that caused 50% or 100% degra-
nulation, none of the peptides had any antagonist activity, even
when pre-incubated with cells at the maximum achievable dose,
100 mM (data not shown).
Fig. 1. Identiﬁcation of hits and target on HMDM using the xCELLigence (a) initial screen of 61 peptides at 8 μM on HMDM (n¼4–6). Asterisk indicates Po0.001. Bars are
shaded according to peptide length (see Supplementary Table 2), (b) dose–response curves for peptides on HMDM (n¼3–5), (c) dose-dependent antagonism of response
using C3a receptor antagonist SB 290157 (SB) when agonized with the EC50 concentrations of hits (n¼3–5), and (d) dose-dependent antagonism of response using C5a1
antagonist PMX53 when agonized with the EC50 concentrations of hits (n¼3–5).
Table 1
Peptides, sequences EC50 and IC50 concentrations (SB 290157) determined for the
ﬁve hits, 20, 31, 47, 49 and 54 identiﬁed in HMDM, using the impedance-based
biosensor, the xCELLigence. The bold-faced letters denote the conserved residues
amongst the sequences.
Peptide number Sequence EC50 (M) IC50 (M)
20 Ac-NNYNLWR 5.8106 1.3109
31 Ac-RHYP LWR 1.1106 6.7108
47 Ac-RLYP LWR 1.2106 4.4108
49 Ac-TI YR LWR 1.7105 1.5108
54 Ac-R YP LWR 3106 2.9108
Fig. 2. xCELLigence response proﬁles for C3a and C5a at 100 nM, and peptides 20,
31, 47, 49 and 54 at 100 μM. A two-peak proﬁle is evident for C5a, whereas a single
peak proﬁle is apparent for C3a. Peptide proﬁles more closely resemble C3a
activation than C5a activation.
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4. Discussion
The design of C5a receptor agonists and antagonists employed
only the structure of C5a. Thus we were only able to use the fold
speciﬁcities as a metric for ranking the sequences. Four separate
ﬂexible templates were used for the design, combining them with
eight runs deﬁning the mutation sets and biological constraints for
a total of 32 runs (see Supplementary Table 1). With all these
combinations, we generated 6400 total sequences. We reduced
this set to 61 sequences (Supplementary Table 2) by selecting the
top few sequences from each run, or highly ranked sequences that
looked interesting based on inspection (e.g. using different muta-
tions not seen in the top ranked sequences). The majority of the
runs reproduced the G73W mutation seen in the potent agonist by
Finch et al. (1999).
These 61 sequences were then synthesized and screened using
the xCELLigence, a label-free impedance-based biosensor, in
human monocyte derived macrophages (HMDM), which have
been shown to express the C5a1 receptor in relatively high
abundance. The xCELLigence was our primary choice for testing
as it is sensitive enough to allow detection in native cells and
provides a pathway independent cell activation response, making
it a useful broad screening tool (Halai and Cooper, 2012). From the
61 peptide set tested, ﬁve clear hits (20, 31, 47, 49 and 54) were
identiﬁed (Fig. 1A).
Interestingly, the receptor signaling proﬁle generated by these
hits more closely resembled that of C3a than C5a1, as highlighted
in Fig. 2. The receptor activation and kinetics between C3a and
C5a1 differ signiﬁcantly, where the evolution of the signal peaks at
1 min after peptide addition for C3a receptor and 4 min after
peptide addition for C5a1. The intensity of the signal varies too,
where a cell index of 1.98 and 4.53 is observed for C3a receptor
and C5a1, respectively. As the receptors for both C3a and C5a are
expressed in HMDM, it is entirely feasible these peptides were
activating C3a receptor instead of C5a1. To discriminate whether
the signal observed for peptides 20, 31, 47, 49 and 54 on HMDM
was attributable to C3a or C5a, a C3a receptor antagonist, SB
290157, and C5a1 antagonist, PMX53, was employed.
C3a receptor antagonist SB 290157 showed a dose-dependent
inhibition of the signal observed for peptides 20, 31, 47, 49 and 54
(Fig. 1C), alluding to C3a receptor being the target receptor for these
hits. These observations were further supported, when no dose-
dependent inhibition of the signal was observed in the presence of
C5a1 antagonist, PMX53 (Fig. 2D), despite incubating at a higher
starting concentration than SB 290157. To further validate this
speciﬁcity, the peptides were tested in RBL-2H3 cells transfected
with either human C5a1 or human C3a receptor. The peptides were
screened as agonists against both C3a receptor and C5a1. As the
results in Fig. 3 show, only C3a receptor responded strongly to the
peptides, with high levels of degranulation produced by a subset of
the peptides identiﬁed in the HMDM screen. The differences in the
screens could be due to receptor expression levels (likely to be
higher in the transfected cell line) or to the different read-out.
Tested as C5a1 antagonists, the peptides had no effect at all
conﬁrming the very weak or absent interaction with this receptor.
Although these peptides were designed using the C-terminal
domain of C5a, they demonstrated activity at C3a receptor, but not
C5a1. C3a receptor/C5a1 promiscuity is not unusual and has been
previously observed for whole C3a and a synthetic peptide agonist
(Ames et al., 1996) and a chimeric C5a with the C3a C-terminal
pentapeptide (Bautsch et al., 1992). In fact, early efforts to create
potent and selective antagonists of C5a1 led to only partial agonists
(Taylor and Fairlie, 2005). This may be due to the fact that most
potent peptides had a mutation of Gly to Pro at position 73,
disrupting the turn conformation of the C-terminus. Researchers
at Merck were some of the ﬁrst to succeed in creating a small
peptide inhibitor of C5a receptors. Their compound, the hexapep-
tide MeFKPdChaFr (N-methylphenylalanine-Lys-Pro-D-cyclohexy-
lalanine-Phe-D-arginine), was shown to be an antagonist but also
had partial agonist behavior (Drapeau et al., 1993). Finch et al.
(1999) optimized the Merck peptide using a cyclization strategy.
Their best antagonist, AcF[OPdChaWR] (AcPhe[Lornithine-Pro-D-
Fig. 3. Agonist activity of peptides at human C5a1 and C3a receptors expressed in rat basophilic leukemia cells (RBL-2H3). Peptides were dissolved in DMSO and incubated at
50 μM with RBL-2H3 cells transfected with the appropriate receptor for 15 min. Degranulation was measured as the secretion of β-hexosaminidase. Results are expressed
relative to maximal stimulation with 200 nM C5a (C5a1) or 100 nM hexapeptide agonist FLPLAR (C3a) after subtraction of background. Statistical signiﬁcance of the
difference from zero was assessed using a one-sample t test (nPo0.05; nnPo0.001). Bars are shaded according to peptide length (see Supplementary Table 2).
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cyclohexylalanine-Trp-Arg], brackets denote cyclization; i.e.
PMX53), had receptor afﬁnity in the low nanomolar range
(Taylor and Fairlie, 2005). Work by the same researchers (Finch
et al., 1997; Kawatsu et al., 1996) also reported the competitive
agonist YSFKDMPLaR (Tyr-Ser-Phe-Lys-Pro-Met-Pro-Leu-D-Ala-
Arg), although this peptide too shows promiscuity for C3a receptor
(Scully et al., 2010). In this study, despite applying our de novo
design framework to ﬁnd novel agonists and antagonists of C5a1,
we identiﬁed novel sequences that agonize the C3a receptor.
Recent evidence (Wu et al., 2013) has shown agonism of the C3a
receptor may have a protective role in acute intestinal injury. Wu
et al. (2013) demonstrated the key role of C3a receptor in regulating
neutrophil mobilization after acute intestinal injury, opening up C3a
receptor agonism as a potential therapeutic avenue. Using the
sequences identiﬁed in this study, new peptide mimetics can be
designed and synthesized. Analysis of the sequences (Supplementary
Table 1) of the active peptides reveals a conserved ‘Leucine (L)-
Tryptophan (W)-Arginine (R)’ sequence at the C termini, as well as a
conserved Tyrosine (Y) two amino acids before the LWR motif. The
Leucine and the Arginine are also found in the same positions at the
C termini in the superagonist ‘W-W-G-K-K-Y-R-A-S-K-L-G-L-A-R’
(Bellows-Peterson et al., 2012; Ember et al., 1991), and seem to be
important for determining the activity towards C3a receptor. This is
not surprising as Ember et al. (1991) described the C terminus
interacting with the primary binding site and the N terminus with
a secondary site. As we have already been able to show activity
towards the C3a receptor, future work to increase potency should
focus on the N termini, more speciﬁcally incorporating hydrophobic
residues that are implicated to form interactions with the secondary
site according to Ember et al. (1991). However, our other peptide
sequences harboring these amino acids did not show any signiﬁcant
activity, so these amino acids may be working in conjunction with
other key residues in the active three-dimensional structural con-
formation to elicit the activity observed.
Systematic and sequential amino acid replacements and trun-
cations of the active peptide sequences may provide further
insight into the key residues critical for the agonist activity
observed at the C3a receptor. This knowledge will be key in
optimizing the potencies of these peptides further, in the hope
of developing them as therapeutics (Reid et al., 2013).
In conclusion, our screen identiﬁed several potent small peptide
C3a receptor agonists. The lack of C5a1 hits, and hits for C3a
receptor indicates promiscuity of C3a receptor and C5a1 ligand
binding sites. Presumably the smaller size of these peptides enabled
binding to C3a receptor. These C3a receptor agonist hits could be
extended towards acute therapies to limit neutrophil mobilization
in disease (Wu et al., 2013) or used as a basis for development of
C3a receptor antagonists for chronic inﬂammatory disease.
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